NAION lawsuits for eyesight side effects associated with Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound seek legal compensation for vision loss or blindness. These NAION lawsuits have been filed in federal courts and state courts over the past couple of years. We are handling these NAION lawsuits filed for people diagnosed with nonarteritic … [Read more...]
NAION Cases Involve Mounjaro, Zepbound, Ozempic, and Wegovy, Other GLP-1 RAs
Nonarteritic anterior ischemic optic neuropathy, or NAION, cases involve Mounjaro, Zepbound, Ozempic, and Wegovy, as well as other glucagon-like peptide-1 receptor agonists (GLP-1RAs), according to an April 2026 medical study report published online by JAMA Network Open. This medical study report, “GLP-1 Receptor Agonists or SGLT2 Inhibitors and … [Read more...]
NAION Lawsuits Involving Ozempic and Mounjaro
As we have reported previously, vision loss due to Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) lawsuits involving Ozempic and Mounjaro are being filed. These NAION lawsuits seek legal compensation for the person suffering from this serious eye side effect injury. Ozempic NAION lawsuits are filed against Novo Nordisk. Mounjaro NAION … [Read more...]
GLP-1 RA Drug NAION Cases: Medical and Legal Updates October 2025
GLP-1 RA Drug NAION Cases: Possible Drug Injury Lawsuits We are investigating possible drug injury lawsuits where people using glucagon-like peptide-I receptor agonist (GLP-1 RA) drugs were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), resulting in vision loss or blindness. Those GLP-1 RA drug NAION cases involve these … [Read more...]
NAION With Mounjaro and Zepbound Being Investigated
The FDA is investigating the possible connection of NAION with Mounjaro and Zepbound, according to “October – December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)”. During the past year, we have written about the vision loss side effect NAION (non-arteritic … [Read more...]